Soleno Therapeutics Updates PWS Launch, Reimbursement Trends and EU Review at Guggenheim Summit

Soleno indicated it is not currently planning to provide full-year guidance , citing the need for the business to mature further and for the company to better understand “ebbs and flows” in launch dynamics, though management said guidance remains “on the table” once it is comfortable.While the company declined to discuss the current quarter’s performance, executives reiterated a longer-term view of launch progress. CEO Anish Bhatnagar said investors should think about roughly 10% of total addressable market ...